More Insulin Innovation To Come, Says Novo CEO Sorensen
This article was originally published in The Pink Sheet Daily
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
You may also be interested in...
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.
Novo Nordisk pushes the benefits of early diabetes treatment to spur Victoza and insulin growth.